COMMUNIQUÉS West-GlobeNewswire

KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
30/07/2025
RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh successfully performed a robotic Ivor Lewis esophagectomy, the first of its kind in the [...]
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
30/07/2025
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...]
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
30/07/2025
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered [...]
Leading European Shipbuilder Selects Aino’s SaaS Platform
30/07/2025
Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the [...]
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE [...]
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
30/07/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA [...]
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
30/07/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar [...]
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30/07/2025
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with [...]
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
30/07/2025
Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis Désignation accordée pour l’anticorps monoclonal GPRC5D à base d’ [...]
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
30/07/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, [...]
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
30/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

Pages